<li>5-htp<p>citalopram and 5-htp both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>abciximab<p>citalopram increases effects of abciximab by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>abiraterone<p>abiraterone increases levels of citalopram by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.</p></li><li>activated charcoal<p>activated charcoal decreases effects of citalopram by pharmacodynamic antagonism. Use Caution/Monitor. Charcoal can reduce absorption of citalopram, resulting in decreased efficacy.</p></li><li>amiodarone<p>amiodarone and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>amphetamine<p>amphetamine increases toxicity of citalopram by serotonin levels. Use Caution/Monitor. Closely monitor for signs and symptoms of serotonin syndrome (eg, agitation, tremor, tachycardia).</p></li><li>anagrelide<p>citalopram increases effects of anagrelide by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>antithrombin iii<p>citalopram increases effects of antithrombin iii by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>apomorphine<p>apomorphine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>argatroban<p>citalopram increases effects of argatroban by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>arsenic trioxide<p>arsenic trioxide and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>asenapine<p>asenapine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>aspirin<p>citalopram, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>aspirin rectal<p>citalopram, aspirin rectal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>citalopram, aspirin/citric acid/sodium bicarbonate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>atazanavir<p>atazanavir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>atomoxetine<p>citalopram increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Although citalopram is a weak inhibitor of 2D6, the potential for an interaction exists.</p></li><li>azithromycin<p>azithromycin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>bedaquiline<p>citalopram and bedaquiline both increase  QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely</p></li><li>bivalirudin<p>citalopram increases effects of bivalirudin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>boceprevir<p>boceprevir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bumetanide<p>bumetanide, citalopram. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>buprenorphine subdermal implant<p>citalopram, buprenorphine subdermal implant.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.</p></li><li>bupropion<p>bupropion will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>carbamazepine<p>carbamazepine decreases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. The possibility that carbamazepine might increase the clearance of citalopram should be considered when both drugs are coadministered.</p></li><li>carvedilol<p>citalopram increases levels of carvedilol by decreasing metabolism. Use Caution/Monitor.</p></li><li>celecoxib<p>citalopram, celecoxib.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>chlorothiazide<p>chlorothiazide, citalopram. pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>chlorpromazine<p>chlorpromazine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>choline magnesium trisalicylate<p>citalopram, choline magnesium trisalicylate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of GI adverse effects may be increased. If possible, avoid concurrent use.</p></li><li>cilostazol<p>citalopram increases effects of cilostazol by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>cimetidine<p>cimetidine increases levels of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>ciprofloxacin<p>ciprofloxacin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>cisapride<p>cisapride and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>clopidogrel<p>citalopram increases effects of clopidogrel by pharmacodynamic synergism. Use Caution/Monitor. SSRIs affect platelet activation; coadministration of SSRIs with clopidogrel may increase the risk of bleeding.</p></li><li>clozapine<p>citalopram increases effects of clozapine by pharmacodynamic synergism. Use Caution/Monitor. Increased risk for serotonin syndrome.</p></li><li>conivaptan<p>conivaptan increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>crizotinib<p>crizotinib increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>crofelemer<p>crofelemer increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclobenzaprine<p>cyclobenzaprine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>cyproheptadine<p>cyproheptadine decreases effects of citalopram by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>dabigatran<p>citalopram increases effects of dabigatran by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>dalteparin<p>citalopram increases effects of dalteparin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>darunavir<p>darunavir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>dasatinib<p>citalopram and dasatinib both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>defibrotide<p>defibrotide increases effects of citalopram by Other (see comment). Use Caution/Monitor. 
Comment: Defibrotide may enhance effects of platelet inhibitors.</p></li><li>degarelix<p>degarelix and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>delavirdine<p>delavirdine increases levels of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>dexmethylphenidate<p>dexmethylphenidate increases effects of citalopram by decreasing metabolism. Use Caution/Monitor. Potential risk for serotonin syndrome or neuroleptic malignant syndrome-like reactions, caution should be observed during coadministration.</p></li><li>dextroamphetamine<p>citalopram and dextroamphetamine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>dichlorphenamide<p>dichlorphenamide and citalopram both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>citalopram, diclofenac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>diflunisal<p>citalopram, diflunisal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>dihydroergotamine<p>citalopram and dihydroergotamine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>dihydroergotamine intranasal<p>citalopram and dihydroergotamine intranasal both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>dipyridamole<p>citalopram increases effects of dipyridamole by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>disopyramide<p>disopyramide and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>dofetilide<p>dofetilide and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>dolasetron<p>dolasetron and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>droperidol<p>droperidol and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>eliglustat<p>eliglustat increases levels of citalopram by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.<span><br><br></span>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of citalopram by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>enoxaparin<p>citalopram increases effects of enoxaparin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>eptifibatide<p>citalopram increases effects of eptifibatide by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>ergotamine<p>citalopram and ergotamine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>erythromycin base<p>erythromycin base increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>erythromycin stearate<p>erythromycin stearate increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate increases levels of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>esomeprazole<p>esomeprazole will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>ethacrynic acid<p>ethacrynic acid, citalopram. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>ethanol<p>ethanol, citalopram.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive CNS depression.</p></li><li>etodolac<p>citalopram, etodolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>ezogabine<p>ezogabine, citalopram.
Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.</p></li><li>fenoprofen<p>citalopram, fenoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>flecainide<p>flecainide and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>fluoxetine<p>citalopram and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>flurbiprofen<p>citalopram, flurbiprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>fondaparinux<p>citalopram increases effects of fondaparinux by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>fosamprenavir<p>fosamprenavir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>foscarnet<p>foscarnet and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>furosemide<p>furosemide, citalopram. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>gemifloxacin<p>gemifloxacin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>green tea<p>green tea, citalopram. Other (see comment). Use Caution/Monitor. 
Comment: Combination may increase risk of bleeding.</p></li><li>heparin<p>citalopram increases effects of heparin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>hydrochlorothiazide<p>hydrochlorothiazide, citalopram. pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>ibuprofen<p>citalopram, ibuprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>ibutilide<p>ibutilide and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>iloperidone<p>iloperidone and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.<span><br><br></span>iloperidone increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>imatinib<p>imatinib increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>indacaterol, inhaled<p>indacaterol, inhaled, citalopram. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.</p></li><li>indapamide<p>indapamide, citalopram. pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.<span><br><br></span>indapamide and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>indinavir<p>indinavir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>indomethacin<p>citalopram, indomethacin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>ioflupane i 123<p>citalopram decreases effects of ioflupane i 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>isradipine<p>isradipine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>itraconazole<p>itraconazole increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoprofen<p>citalopram, ketoprofen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>ketorolac<p>citalopram, ketorolac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>ketorolac intranasal<p>citalopram, ketorolac intranasal.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>lamotrigine<p>lamotrigine increases toxicity of citalopram by unspecified interaction mechanism. Modify Therapy/Monitor Closely. CNS depressants may increase the toxic effects of selective serotonin reuptake inhibitors; psychomotor impairment may be enhanced.</p></li><li>lapatinib<p>lapatinib and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>lenvatinib<p>citalopram and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.</p></li><li>lepirudin<p>citalopram increases effects of lepirudin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>levofloxacin<p>levofloxacin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>lisdexamfetamine<p>citalopram, lisdexamfetamine.
Either increases effects of the other by unknown mechanism. Use Caution/Monitor. Risk of serotonin syndrome.<span><br><br></span>citalopram and lisdexamfetamine both increase  serotonin levels. Use Caution/Monitor.</p></li><li>lithium<p>citalopram, lithium. Mechanism: unknown. Use Caution/Monitor. Lithium may enhance the serotonergic effects of citalopram, caution should be exercised when citalopram and lithium are coadministered.</p></li><li>lopinavir<p>lopinavir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>lorcaserin<p>lorcaserin will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, citalopram. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .<span><br><br></span>lumacaftor/ivacaftor will decrease the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. A higher dose of citalopram may be required to obtain desired therapeutic effect. Citalopram is a CYP3A and CYP2C19 substrate. Lumacaftor/ivacaftor is a strong inducer of CYP3A and has the potential to induce CYP2C19.</p></li><li>lumefantrine<p>lumefantrine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>lurasidone<p>lurasidone, citalopram.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.</p></li><li>maprotiline<p>citalopram and maprotiline both increase  serotonin levels. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>meclofenamate<p>citalopram, meclofenamate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>mefenamic acid<p>citalopram, mefenamic acid.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>meloxicam<p>citalopram, meloxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>meperidine<p>citalopram and meperidine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>methadone<p>methadone and citalopram both increase  QTc interval. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome like reactions. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>methamphetamine<p>methamphetamine, citalopram.
Either increases effects of the other by unknown mechanism. Use Caution/Monitor. Risk of serotonin syndrome.</p></li><li>methyclothiazide<p>methyclothiazide, citalopram. pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>methylphenidate<p>methylphenidate increases effects of citalopram by decreasing metabolism. Use Caution/Monitor. Potential risk for serotonin syndrome or neuroleptic malignant syndrome-like reactions, caution should be observed during coadministration.</p></li><li>metolazone<p>metolazone, citalopram. pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>metoprolol<p>citalopram increases levels of metoprolol by decreasing metabolism. Use Caution/Monitor. Increased metoprolol plasma levels have been associated with decreased cardioselectivity.</p></li><li>mifepristone<p>mifepristone, citalopram. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.</p></li><li>mirabegron<p>mirabegron will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.</p></li><li>mirtazapine<p>citalopram and mirtazapine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>mitotane<p>mitotane decreases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>modafinil<p>modafinil will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>morphine<p>citalopram and morphine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>moxifloxacin<p>moxifloxacin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>nabumetone<p>citalopram, nabumetone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>naproxen<p>citalopram, naproxen.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>nefazodone<p>nefazodone increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>nelfinavir<p>nelfinavir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. .</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nicardipine<p>nicardipine increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nilotinib<p>nilotinib and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>norfloxacin<p>norfloxacin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>octreotide<p>octreotide and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>ofloxacin<p>ofloxacin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>olodaterol inhaled<p>citalopram and olodaterol inhaled both increase  QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias</p></li><li>omeprazole<p>omeprazole will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>osimertinib<p>osimertinib and citalopram both increase  QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.</p></li><li>oxaprozin<p>citalopram, oxaprozin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>oxycodone<p>oxycodone increases effects of citalopram by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Opioids may enhance the serotonergic effects of SSRIs and increase risk for serotonergic syndrome.</p></li><li>paliperidone<p>paliperidone and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>pasireotide<p>citalopram and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely.</p></li><li>pazopanib<p>pazopanib and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>pentamidine<p>pentamidine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>pentazocine<p>citalopram and pentazocine both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>piroxicam<p>citalopram, piroxicam.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome like reactions. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>prasugrel<p>citalopram increases effects of prasugrel by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>procainamide<p>procainamide and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>prochlorperazine<p>citalopram and prochlorperazine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>promethazine<p>citalopram and promethazine both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>propafenone<p>propafenone and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>propranolol<p>citalopram increases levels of propranolol by decreasing metabolism. Use Caution/Monitor.</p></li><li>quetiapine<p>quetiapine, citalopram.
Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT interval and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.  ECG monitoring is recommended.</p></li><li>quinidine<p>quinidine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>quinine<p>quinine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>ranolazine<p>ranolazine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>rifampin<p>rifampin will decrease the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>rilpivirine<p>rilpivirine increases toxicity of citalopram by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.</p></li><li>risperidone<p>citalopram will increase the level or effect of risperidone by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>ritonavir<p>ritonavir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased risk of serotonin syndrome. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>rivaroxaban<p>citalopram increases effects of rivaroxaban by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>romidepsin<p>romidepsin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>safinamide<p>citalopram, safinamide.
Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Monitor patients for symptoms of serotonin syndrome if SSRIs are coadministered with safinamide.</p></li><li>salicylates (non-asa)<p>citalopram, salicylates (non-asa).
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>salsalate<p>citalopram, salsalate.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>saquinavir<p>saquinavir and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>citalopram, sodium sulfate/potassium sulfate/magnesium sulfate. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>citalopram, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. 
Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.</p></li><li>sorafenib<p>sorafenib and citalopram both increase  QTc interval. Use Caution/Monitor.</p></li><li>sotalol<p>sotalol and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>sulindac<p>citalopram, sulindac.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>sunitinib<p>sunitinib and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>tacrolimus<p>tacrolimus and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>tapentadol<p>citalopram and tapentadol both increase  serotonin levels. Modify Therapy/Monitor Closely.</p></li><li>telaprevir<p>telaprevir will decrease the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>telavancin<p>telavancin and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>telithromycin<p>telithromycin increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>thiothixene<p>thiothixene and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>ticagrelor<p>citalopram increases effects of ticagrelor by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>ticlopidine<p>ticlopidine increases levels of citalopram by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>timolol<p>citalopram increases levels of timolol by decreasing metabolism. Use Caution/Monitor.</p></li><li>tinzaparin<p>citalopram increases effects of tinzaparin by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>tipranavir<p>tipranavir increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tirofiban<p>citalopram increases effects of tirofiban by pharmacodynamic synergism. Use Caution/Monitor. Combination may increase risk of bleeding.</p></li><li>tizanidine<p>citalopram will increase the level or effect of tizanidine by  Other (see comment). Use Caution/Monitor. Monitor for increased psychomotor impairment and adverse effects.</p></li><li>tolmetin<p>citalopram, tolmetin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>toremifene<p>toremifene and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>torsemide<p>torsemide, citalopram. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Possible additive hyponatremia.</p></li><li>tramadol<p>citalopram and tramadol both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>trazodone<p>citalopram and trazodone both increase  serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>valerian<p>valerian and citalopram both increase  sedation. Use Caution/Monitor.</p></li><li>vandetanib<p>vandetanib and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>vardenafil<p>vardenafil and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>vorapaxar<p>citalopram, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur; SSRIs and SNRIs may cause platelet serotonin depletion .</p></li><li>voriconazole<p>voriconazole increases levels of citalopram by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>vorinostat<p>vorinostat and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.</p></li><li>warfarin<p>citalopram increases levels of warfarin by decreasing metabolism. Use Caution/Monitor. Coadministration of warfarin and citalopram increased prothrombin time by 5%. Use caution with coadministration and monitor patient.</p></li>